Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
  • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
  • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
  • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
  • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
  • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
  • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
  • C07D473/28—Oxygen atom
  • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
  • C07D473/36—Sulfur atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
  • C07D513/04—Ortho-condensed systems

Definitions

• the invention relates to agents that inhibit hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp).
• HCV hepatitis C virus
• RdRp RNA-dependent RNA polymerase
• HCV is an enveloped RNA virus containing a single-stranded positive-sense RNA genome approximately 9.5 kb in length (Choo et al., Science 244:359-362 (1989)).
• the RNA genome contains a 5'-nontranslated region (5' NTR) of 341 nucleotides (Brown et al., Nucl. Acids Res. 20:5041-5045 (1992); Bukh et al., Proc. Natl. Acad. Sci. USA 89:4942-4946 (1992)), a large open reading frame (ORF) encoding a single polypeptide of 3,010 to 3,040 amino acids (Choo et al.
• the 5' NTR is one of the most conserved regions of the viral genome and plays a pivotal role in the initiation of translation of the viral polyprotein (Bartenschlager (1997), supra).
• a single ORF encodes a polyprotein that is co- or post-translationally processed into structural (core, E1, and E2) and nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) viral proteins by either cellular or viral proteinases (Bartenschlager (1997), supra).
• the 3' NTR consists of three distinct regions: a variable region of about 38 nucleotides following the stop codon of the polyprotein, a polyuridine tract of variable length with interspersed substitutions of cystines, and 98 nucleotides (nt) at the very 3' end which are highly conserved among various HCV isolates.
• Hepatitis C virus is a member of the hepacivirus genus in the family Flaviviridae. It is the major causative agent of non-A, non-B viral hepatitis and is the major cause of transfusion- associated hepatitis and accounts for a significant proportion of hepatitis cases worldwide. Although acute HCV infection is often asymptomatic, nearly 80% of cases resolve to chronic hepatitis.
• HCV polyprotein is first cleaved by a host signal peptidase generating the structural proteins C/E1, E1/E2, E2/p7, and p7/NS2 (Hijikata et al., Proc. Natl. Acad. Sci. USA 88:5547-5551 (1991); Lin et al., J. Virol. 68:5063-5073 (1994)).
• NS2-3 proteinase which is a metalloprotease, then cleaves at the NS2/NS3 junction.
• the NS3/4A proteinase complex (NS3 serine protease/NS4A cofactor), then at all the remaining cleavage sites (Bartenschlager et al., J. Virol. 67:3835-3844 (1993); Bartenschlager (1997), supra).
• RNA helicase and NTPase activities have also been identified in the NS3 protein.
• NS5A may be phosphorylated and act as a putative cofactor of NS5B.
• the fourth viral enzyme, NS5B is an RNA-dependent RNA polymerase (RdRp) and a key component responsible for replication of the viral RNA genome (Lohmann et al., J. Virol. 71:8416- 8428 (1997)).
• RNA-dependent RNA polymerase activity RdRp
• NS5B While the role of NS3 in RNA replication is less clear, NS5B apparently is the key enzyme responsible for synthesis of progeny RNA strands.
• baculoviruses to express NS5B in insect cells and a synthetic nonviral RNA as a substrate, two enzymatic activities have been identified as being associated with NS5B. The two activities include a primer-dependent RdRp and a terminal transferase (TNTase) activity.
• TNTase terminal transferase
• the present invention relates to compounds of the formula 1
• R 2 is selected from the group of R 1 substituents, -(CR 8 R 9 ) t (C 6 -C 10 aryl), -(CR 8 R 9 ) t (4-10 membered heterocyclic), -(CR 8 R 9 ) q C(O)(CR 8 R 9 ) t (C 6 -C 10 aryl), -(CR 8 R 9 ) q C(O)(CR 8 R 9 ) t (4-10 membered heterocyclic), -(CR 8 R 9 ) t O(CR 8 R 9 ) q (C 6 -C 10 aryl), -(CR 8 R 9 ) t O(CR 8 R 9 ) q (4-10 membered heterocyclic), -(CR 8 R 9 ) q SO n (CR 8 R 9 )t(C 6 -C 10 aryl), and -(CR 8 R 9 ) q SO n (CR 8 R 9 ) t (4-10 membered heterocyclic), wherein
• R 3' is selected from the group of R 3 substituents except R 3' is not H; each R 4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C r C ⁇ 0 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C(0)R 6 , -C(0)OR 6 , -OC(0)R 6 , -NR 6 C(0)R 7 , -NR 6 C(0)NR 7 , -C(0)NR 6 R 7 , -NR 6 R 7 , -NR 6 OR 7 , -S0 2 NR 6 R 7 , -NR 6 S0 2 R 7 , -(CR 8 R 9 ) t (C 6 -C 10 aryl)(wherein t is an integer from 0 to 5), -(CR 8 R 9 ) t (4-10 membered heterocyclic)(wherein t is an integer from 0 to 5),
• each R 8 and R 9 is independently selected from H and C C alkyl; and each R 10 is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, -C(0)0-R 6 , -OR 6 , -C(0)(CR 8 R 9 ) p C(0)OR 6 , wherein p is an integer from
• R 2 is selected from the group of R 1 substituents, -(CR 8 R 9 ) (C 3 -C 10 cycloalkyl), - (CR 8 R 9 ) t (C 6 -C 10 aryl), -(CR 8 R 9 ) t (4-10 membered heterocyclic), -(CR 8 R 9 ) q C(O)(CR 8 R 9 ) t (C 6 -C 10 aryl), -(CR 8 R 9 ) q C(O)(CR 8 R 9 ) t (4-10 membered heterocyclic), -(CR 8 R 9 ),O(CR 8 R 9 ) q (C 6 -C 10 aryl), -(CR 8 R 9 ) t O(CR 8 R 9 ) q (4-10 membered heterocyclic), -(CR 8 R 9 ) q SO n (CR 8 R 9 ) t (C 6 -C 10 aryl), and
• R 3 is hydrogen, -OR 6 , -SR 8 , -NR 6 R 7 , and the group of R 2 substituents;
• R 3' is selected from the group of R 3 substituents; each R 4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C C ⁇ 0 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, - (CR 8 R 9 ),N(R 5 ) 2 , -(CR 8 R 9 ) t NR 6 C(0)R 6 , -(CR 8 R 9 ) t OR 6 , -(CR 8 R 9 ) t C(0)R 6 , -(CR 8 R 9 ) t C(0)OR 6 , - (CR 8 R 9 ) t C(0)R 6 , -(CR 8 R 9 ), NR 6 C(0)R 7 , -(CR 8 R 9 ) t NR 6 C(0)OR 6 -(CR 8 R 9 ) t NR 6 C(0)NR 7
• R 1 is cyclopentyl
• R 2 is -(CR 8 R 9 ) t (C 6 -C 10 aryl) or -(CR 8 R 9 ) t (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R 2 groups are optionally substituted by 1 to 5 R 4 groups, and with the proviso that R 2 is not H;
• R 3 is hydrogen, -OR 6 , -SR 6 , -NR 6 R 7 , and the group of R 2 substituents; each R 4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C r C 10 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C(0)R 6 , -C(0)OR 6 , -OC(0)R 8 , -NR 6 C(0)R 7 , -NR 6 C(0)NR 7 , -C(0)NR
• the present invention further relates to a compound of the formula (3)
• R 1 is cyclopentyl;
• R 2 is -(CR 8 R 9 ) t (C 6 -C 10 aryl) or -(CR 8 R 9 ),(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R 2 groups are optionally substituted by 1 to 5 R 4 groups, and with the proviso that R 2 is not H;
• R 3 is hydrogen;
• each R 4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C r C 10 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C(0)R 6 , -C(0)OR 6 , -OC(0)R 6 ,
• R 2 is - (CR 8 R 9 ) t (C 6 -C 10 aryl), wherein t is an integer from 2 to 5, and the aryl moiety of said R 2 group is optionally substituted by 1 to 5 R 4 groups, and with the proviso that R 2 is not H; optionally each R 4 is independently selected from halo, nitro, C C 10 alkyl, -C(0)R 6 , -C(0)OR 6 , -OC(0)R 6 ,
• R 1 is cyclopentyl
• R 3 is -(CR 8 R 9 ) t (C 6 -C 10 aryl) or -(CR 8 R 9 ) t (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R 3 groups are optionally substituted by 1 to 5 R 4 groups; each R 4 is independently chosen from halo, C r C 10 alkyl, and R 6 -0-, and each C r C 10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C ⁇ 0 alkyl, and cyano; or when two adjacent R 4 groups are both C C ⁇ o alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, 0, and S, provided that two adjacent carbons are not both replaced by heteroatoms
• R 8 and R 9 are independently chosen from hydrogen and C C 10 alkyl; z is an integer from 1 to 5; and y is an integer from 0 to 5.
• R 1 is cyclopentyl
• R 3 is -(CR 8 R 9 )t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the heterocyclic moiety is optionally substituted by 1 to 5 R 4 groups; each R 4 is independently chosen from halo, C C ⁇ 0 alkyl, and R 6 -0-, and each C C 10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C 10 alkyl, and cyano; or when two adjacent R 4 groups are both C C 10 alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, O, and S, provided that two adjacent carbons are not both replaced by heteroatoms;
• R 6 is hydrogen or C C 10 alkyl
• R 8 and R 9 are hydrogen
• z is an integer from 1 to 5
• y is an integer from 0 to 5.
• R 1 is cyclopentyl;
• R 3 is -(CH 2 ) t ([1 ,2,4]triazolo[1 ,5-a]pyrimidyl), optionally substituted by 1 to 3 R 4 groups;
• t is an integer from 1-3;
• each R 4 is independently chosen from halo, C C ⁇ alkyl, and R 6 -0-, and each CrC 10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C 10 alkyl, and cyano; or when two adjacent R 4 groups are both C C ⁇ o alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, O, and S, provided that two adjacent carbons are not both replaced by heteroatoms;
• R 6 is hydrogen or C C 10 alkyl;
• R is cyclopentyl
• R 3 is -(CH 2 )([1,2,4]triazolo[1,5-a]pyrimidyl), substituted by 1 to 3 R 4 groups; each R 4 is independently chosen from halo and C ⁇ -C 10 alkyl optionally substituted with cyano; or two adjacent R 4 groups are both C C ⁇ 0 alkyl and, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein a carbon atom is replaced by a heteroatom chosen from N, O, and S; z is an integer from 2 to 3; and y is 2.
• R 1 is cyclopentyl
• R 3 is -(CH 2 )([1,2,4]triazolo[1,5-a]pyrimidyl), substituted by 2 R 4 groups; each R 4 is independently chosen from halo, -CH 3 , and -C(CH 3 ) 2 CN; and y is 2.
• R 3 is -(CH 2 )([1,2,4]triazolo[1,5-a]pyrimidyl), substituted by at least one substituent chosen from halo and methyl; two adjacent R 4 groups, together with the atoms to which they are attached form a 5- membered ring, wherein in said ring one carbon atom is replaced by O; z is an integer from 2 to 3; and y is 2.
• R 3 is -(CH 2 )([1 ,2,4]triazolo[1 ,5-a]pyrimidyl), substituted by at least one substituent chosen from halo and methyl;
• Q is chosen from N, O, and S;
• R 4a , R 4 , and R 4c are independently chosen from hydrogen, halo, C C 10 alkyl, and R 6 -0-;
• R 6 is chosen from hydrogen and C C 10 alkyl.
• Another aspect of the present invention provides compounds of formula (5),
• R 4a , R 4b , and R c are independently chosen from halo and C C 10 alkyl;
• R 4d , R e , and R 4f are independently chosen from halo, R 6 -0-, and C C ⁇ o alkyl, wherein said C 1 -C 10 alkyl is optionally substituted with at least one substituent chosen from halo and cyano; and
• R 6 is C C 10 alkyl or hydrogen.
• Another aspect of the present invention provides compounds of formula (6),
• R is halo
• Another aspect of the present invention provides compounds of formula (8),
• R 4 is halo
• Still a further aspect of the present invention provides compounds of formulas (6), (7), and (8), wherein R 4 is chosen from fluorine and chlorine. In yet another aspect of the present invention are provided compounds of formulas (6), (7), and (8), wherein R 4 is fluorine. In still a further aspect are provided those compounds of formula (6), (7), and (8), wherein R 4 is chlorine.
• Another aspect of the present invention provides compounds of formula (4), wherein:
• R 1 is cyclopentyl
• R 3 is -(CH 2 )([1,2,4]triazolo[1,5-a]pyrimidyl), optionally substituted by 1 to 3 R 4 groups; each R 4 is independently chosen from halo, C ⁇ -C 10 alkyl, and R 6 -0-, and each C 1 -C 10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C r C 10 alkyl, and cyano;
• R 6 is hydrogen or C C 10 alkyl; z is an integer from 1 to 3; and y is 2.
• R >1 ; is, cyclopentyl
• R 3 is -(CH 2 )([1 ,2,4]triazolo[1,5-a]pyrimidyI), optionally substituted by 1 to 3 R 4 groups; each R 4 is independently chosen from halo, C ⁇ -C 10 alkyl, and R 6 -0-, and each C r C 10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C 10 alkyl, and cyano; R 6 is hydrogen or methyl; z is an integer from 2-3; and y is 2.
• R 4a is halo or C C 10 alkyl
• R 4 , R c , and R 4d are independently chosen from C C 10 alkyl and R 6 -0-;
• R 6 is hydrogen or methyl.
• R 4a is halo
• R b and R c are each R 6 -0-;
• R 4d is C C ⁇ o alkyl
• R 6 is hydrogen or methyl.
• R ,a is fluorine or chlorine
• R" D is -OCH 3 ;
• R ,c is -OH; and a d
• R w is -CH 2 CH 3 .
• R 4a is chlorine
• R 40 is -OH
• R 4d is -CH 2 CH 3 .
• Another aspect of the present invention provides compounds of formula (10),
• Still a further aspect of the present invention provides compounds of formula (11),
• the invention relates to a compound selected from the group consisting of:
• the present invention also provides compounds chosen from:
• compounds chosen from: (+)-2-(2-fluoro-4- ⁇ 2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl ⁇ -phenyl)-2-methyl-propionitrile;
• the invention also relates to a method for the treatment of Hepatitis C virus (HCV) in a mammal, such as a human, comprising administering to said mammal an amount of a compound of the present invention or a salt or solvate thereof that is effective in treating HCV.
• HCV Hepatitis C virus
• a mammal such as a human, suffering from infection with Hepatitis C virus
• methods for the treatment of a mammal comprising administering to said mammal a Hepatitis C virus-inhibiting amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof.
• the present invention also relates to a method of inhibiting Hepatitis C polymerase, comprising contacting said polymerase with a polymerase-inhibiting amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof.
• the present invention is also directed to a pharmaceutical composition for the treatment of Hepatitis C virus (HCV) in a mammal, such as a human, comprising an amount of a compound the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof, that is effective in treating HCV, and a pharmaceutically acceptable carrier.
• HCV Hepatitis C virus
• the present invention is also directed to inhibition of Hepatitis C virus replication in a mammal, such as a human, comprising administering to said mammal a Hepatitis C virus replication-inhibiting amount of a compound of the present invention.
• the present invention is further directed to a method of inhibiting HCV RdRp activity, comprising contacting the protein with an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof.
• HCV activity may be inhibited in mammalian tissue by administering an HCV-inhibiting agent according to the invention.
• the present invention also relates to the use of the compounds of the invention in the preparation of a medicament for the treatment of a mammal suffering from infection with Hepatitis C virus.
• the medicament may comprise a Hepatitis C virus-inhibiting amount of a compound or compounds of the invention and a pharmaceutically acceptable carrier or carriers.
• a pharmaceutically acceptable carrier or carriers As used herein, the terms “comprising” and “including” are used in their open, non- limiting sense.
• the compounds of the present invention may exist in several tautomeric forms.
• a compound of the invention may exist in a form in which two ketones are present on a ring of the compound, as shown in (A) below.
• the compounds of the present invention may exist in at least two different enol forms, as shown in compounds (B) and (C) below. These three forms may be in equilibrium and the compounds of the invention may exist in more than one of these forms at the same time.
• a certain percentage of the molecules may be present in form (A) while the remainder are present in form (B) or form (C).
• C C 6 alkyl includes saturated monovalent hydrocarbon radicals having straight, branched, or cyclic moieties (including fused and bridged bicyclic and spirocyclic moieties), or a combination of the foregoing moieties, and containing from 1-6 carbon atoms.
• the group For an alkyl group to have cyclic moieties, the group must have at least three carbon atoms.
• a "lower alkyl” is intended to mean an alkyl group having from 1 to 4 carbon atoms in its chain.
• heteroalkyl refers to a straight- or branched-chain alkyl group having from 2 to
• heteroalkyls include alkyl ethers, secondary and tertiary amines, alkyl sulfides and the like.
• C 2 -C 6 alkenyl includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above and including E and Z isomers of said alkenyl moiety, and having from 2 to 6 carbon atoms.
• C 2 -C 6 alkynyl includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above, and containing from 2-6 carbon atoms.
• carbocycle refers to a saturated, partially saturated, unsaturated, or aromatic, monocyclic or fused or non-fused polycyclic, ring structure having only carbon ring atoms (no heteroatoms, i.e., non-carbon ring atoms).
• exemplary carbocycles include cycloalkyl, aryl, and cycloalkyl-aryl groups.
• C 3 -C 10 cycloalkyl group is intended to mean a saturated or partially saturated, monocyclic, or fused or spiro polycyclic, ring structure having a total of from 3 to 10 carbon ring atoms (but no heteroatoms).
• exemplary cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, adamantyl, and like groups.
• heterocycloalkyl group is intended to mean a monocyclic, or fused or spiro polycyclic, ring structure that is saturated or partially saturated, and has a total of from 3 to 18 ring atoms, including 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur.
• heterocycloalkyl groups include pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, and like groups.
• C 6 -C 10 aryl as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
• Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system.
• the heterocyclic groups include benzo-fused ring systems.
• An example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine).
• An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl.
• non- aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiehyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, di
• aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinox
• a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
• a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached).
• heteroaryl group is intended to mean a monocyclic or fused or spiro polycyclic, aromatic ring structure having from 4 to 18 ring atoms, including from 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur.
• heteroaryl groups include pyrrolyl, thienyl, oxazolyl, pyrazolyl, thiazolyl, furyl, pyridinyl, pyrazinyl, triazolyl, tetrazolyl, indolyl, quinolinyl, quinoxalinyl, benzthiazolyl, benzodioxinyl, benzodioxolyl, benzooxazolyl, and the like.
• alkoxy as used herein, unless otherwise indicated, includes O-alkyl groups wherein alkyl is as defined above.
• amino is intended to mean the -NH 2 radical.
• halogen and halo, as used herein represent chlorine, fluorine, bromine or iodine.
• trifluoromethyl is meant to represent a group -CF 3 .
• trifluoromethoxy is meant to represent a group -OCF 3 .
• cyano as used herein, is meant to represent a group -CN.
• substituted means that the specified group or moiety bears one or more substituents.
• unsubstituted means that the specified group bears no substituents.
• optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents.
• HCV refers to Hepatitis C virus.
• the term "inhibiting Hepatitis C virus” means inhibiting Hepatitis C virus replication in a mammal, such as a human, by administering to the mammal a Hepatitis C virus-inhibiting amount of a compound of the invention.
• the amount of inhibition of Hepatitis C virus replication in a mammal can be measured using methods known to those of ordinary skill in the art. For example, an amount of a compound of the invention may be administered to a mammal, either alone or as part of a pharmaceutically acceptable formulation. Blood samples may then be withdrawn from the mammal and the amount of Hepatitis C virus in the sample may be quantified using methods known to those of ordinary skill in the art.
• a reduction in the amount of Hepatitis C virus in the sample compared to the amount found in the blood before administration of a compound of the invention would represent inhibition of the replication of Hepatitis C virus in the mammal.
• the administration of a compound of the invention to the mammal may be in the form of single dose or a series of doses over successive days.
• HCV-inhibiting agent means a compound of the present invention or a pharmaceutically acceptable salt, hydrate, prodrug, active metabolite or solvate thereof.
• HCV-inhibiting amount refers to an amount of a compound of the present invention that is sufficient to inhibit the replication of the Hepatitis C virus when administered to a mammal, such as a human.
• HCV polymerase-inhibiting amount means an amount of a compound of the present invention that is sufficient to inhibit the function of the Hepatitis C virus polymerase enzyme when the compound is placed in contact with the enzyme.
• a “prodrug” is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt of such compound.
• a prodrug containing such a moiety may be prepared according to conventional procedures by treatment of a hydroxamate derivative of this invention containing, for example, an amido, carboxylic acid, or hydroxyl moiety with a suitable reagent.
• an "active metabolite” is a pharmacologically active product produced through metabolism in the body of a specified hydroxamate derivative or salt thereof.
• Prodrugs and active metabolites of the hydroxamate derivative may be identified using routine techniques known in the art. See, e.g., Bertolini et al., J. Med. Chem., 40:2011-2016 (1997); Shan et al., J. Pharm. Sci., 86 (7):765-767 (1997); Bagshawe, Drug Dev.
• a “solvate” is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound.
• solvates include compounds of the invention in combination with solvents such as, but not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
• solvents such as, but not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
• a “pharmaceutically acceptable salt” is intended to mean a salt that retains the biological effectiveness of the free acids and bases of the specified derivative and that is not biologically or otherwise undesirable.
• Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1 ,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phen
• treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
• treatment refers to the act of treating as “treating” is defined immediately above.
• phrases "pharmaceutically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups, which may be present in the compounds of the present invention.
• the compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
• acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of the present invention are those that form non-toxic acid addition salts, e , salts containing pharmacologically acceptable anions, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edislyate, estolate, esylate, ethylsuccinate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate
• terapéuticaally effective amount is intended to mean the amount of an inventive agent that, when administered to a mammal in need of treatment, is sufficient to effect treatment for injury or disease conditions alleviated by the inhibition of HCV RNA replication such as for potentiation of anti-cancer therapies or inhibition of neurotoxicity consequent to stroke, head trauma, and neurodegenerative diseases.
• the amount of a given HCV-inhibiting agent used in the method of the invention that will be therapeutically effective will vary depending upon factors such as the particular HCV- inhibiting agent, the disease condition and the severity thereof, the identity and characteristics of the mammal in need thereof, which amount may be routinely determined by artisans.
• the compounds of the present invention may have asymmetric carbon atoms.
• the carbon-carbon bonds of the compounds of the present invention may be depicted herein using a solid line ( ), a solid wedge ( """ ⁇ — m ), or a dotted wedge ( '"" ).
• the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers at that carbon atom are included.
• the use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom.
• a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included.
• the use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
• Solutions of individual stereoisomeric compounds of the present invention may rotate plane-polarized light.
• the use of either a "(+)" or “(-)” symbol in the name of a compound of the invention indicates that a solution of a particular stereoisomer rotates plane-polarized light in the (+) or (-) direction, as measured using techniques known to those of ordinary skill in the art.
• Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
• Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention. Alternatively, individual stereoisomeric compounds of the present invention may be prepared in enantiomerically enriched form by asymmetric synthesis.
• an appropriate optically active compound e.g., alcohol
• converting e.g., hydrolyzing
• Asymmetric synthesis may be performed using techniques known to those of skill in the art, such as the use of asymmetric starting materials that are commercially available or readily prepared using methods known to those of ordinary skill in the art, the use of asymmetric auxiliaries that may be removed at the completion of the synthesis, or the resolution of intermediate compounds using enzymatic methods.
• the choice of such a method will depend on factors that include, but are not limited to, the availability of starting materials, the relative efficiency of a method, and whether such methods are useful for the compounds of the invention containing particular functional groups. Such choices are within the knowledge of one of ordinary skill in the art.
• the derivative salts, prodrugs and solvates may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the scope of the present invention.
• an optically pure compound is one that is enantiomerically pure.
• the term "optically pure” is intended to mean a compound comprising at least a sufficient activity.
• an optically pure amount of a single enantiomer to yield a compound having the desired pharmacological pure compound of the invention comprises at least 90% of a single isomer (80% enantiomeric excess), more preferably at least 95% (90% e.e.), even more preferably at least 97.5% (95% e.e.), and most preferably at least 99% (98% e.e.).
• a desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid; hydrobromic acid; sulfuric acid; nitric acid; phosphoric
• ⁇ acid and the like, or with an organic acid, such as acetic acid; maleic acid; succinic acid; mandelic acid; fumaric acid; malonic acid; pyruvic acid; oxalic acid; glycolic acid; salicylic acid; pyranosidyl acid, such as glucuronic acid or galacturonic acid; alpha-hydroxy acid, such as citric acid or tartaric acid; amino acid, such as aspartic acid or glutamic acid; aromatic acid, such as benzoic acid or cinnamic acid; sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid; and the like.
• organic acid such as acetic acid; maleic acid; succinic acid; mandelic acid; fumaric acid; malonic acid; pyruvic acid; oxalic acid; glycolic acid; salicylic acid; pyranosidyl acid, such as glucuronic acid or galacturonic
• a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like.
• suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
• derivatives, prodrugs, salts, or solvates that are solids
• the derivatives, prodrugs, salts, and solvates used in the method of the invention may exist in different polymorph or crystal forms, all of which are intended to be within the scope of the present invention and specified formulas.
• the derivative, salts, prodrugs and solvates used in the method of the invention may exist as tautomers, all of which are intended to be within the broad scope of the present invention.
• the compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
• the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
• the desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
• Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
• such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
• the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form nontoxic base salts with the acidic compounds of the present invention.
• Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc.
• salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
• they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
• stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
• the activity of the compounds as inhibitors of HCV activity may be measured by any of the suitable methods available in the art, including in vivo and in vitro assays.
• An Example of a suitable assay for activity measurements is the HCV replicon assay described herein.
• Administration of the compounds and their pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates may be performed according to any of the accepted modes of administration available to those skilled in the art.
• suitable modes of administration include oral, nasal, parenteral, topical, transdermal, and rectal. Oral and intravenous deliveries are preferred.
• An HCV-inhibiting agent of the present invention may be administered as a pharmaceutical composition in any suitable pharmaceutical form.
• suitable pharmaceutical forms include solid, semisolid, liquid, or lyopholized formulations, such as tablets, powders, capsules, suppositories, suspensions, liposomes, and aerosols.
• the HCV-inhibiting agent may be prepared as a solution using any of a variety of methodologies.
• the HCV-inhibiting agent can be dissolved with acid (e.g., 1 M HCl) and diluted with a sufficient volume of a solution of 5% dextrose in water (D5W) to yield the desired final concentration of HCV-inhibiting agent (e.g., about 15 mM).
• a solution of D5W containing about 15 mM HCl can be used to provide a solution of the HCV-inhibiting agent at the appropriate concentration.
• the HCV- inhibiting agent can be prepared as a suspension using, for example, a 1% solution of carboxymethylcellulose (CMC).
• compositions are known or may be routinely determined by those skilled in the art.
• pharmaceutical preparations may be prepared following conventional techniques of the pharmaceutical chemist involving steps such as mixing, granulating, and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural, and/or rectal administration.
• compositions of the invention may also include suitable excipients, diluents, vehicles, and carriers, as well as other pharmaceutically active agents, depending upon the intended use.
• Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles, or excipients may be employed in the pharmaceutical compositions.
• Illustrative solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, pectin, acacia, magnesium stearate, and stearic acid.
• Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution, and water.
• the carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
• a suitable prolonged-release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
• the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., solution), or a nonaqueous or aqueous liquid suspension.
• a dose of the pharmaceutical composition may contain at least a therapeutically effective amount of an HCV-inhibiting agent and preferably is made up of one or more pharmaceutical dosage units.
• the selected dose may be administered to a mammal, for example, a human, in need of treatment mediated by inhibition of HCV activity, by any known or suitable method of administering the dose, including topically, for example, as an ointment or cream; orally; rectally, for example, as a suppository; parenterally by injection; intravenously; or continuously by intravaginal, intranasal, intrabronchial, intraaural, or intraocular infusion.
• the composition When the composition is administered in conjunction with a cytotoxic drug, the composition can be administered before, with, and/or after introduction of the cytotoxic drug. However, when the composition is administered in conjunction with radiotherapy, the composition is preferably introduced before radiotherapy is commenced.
• a dose that may be employed is from about 0.001 to about 1000 mg/kg body weight, preferably from about 0.1 to about 100 mg/kg body weight, and even more preferably from about 1 to about 50 mg/kg body weight, with courses of treatment repeated at appropriate intervals.
• the subject invention also includes isotopically-labelled compounds, which are identical to those recited in the compounds of the present invention, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
• isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 1 ⁇ O, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 Ci, respectively.
• Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
• isotopically-labelled compounds of the present invention for example those into which radioactive isotopes such as 3 H and 1 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2 H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
• Isotopically labelled compounds of the present invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
• Et2 ⁇ diethyl ether
• DMF N,N- dimethylformamide
• DMSO dimethylsulfoxide
• MeOH methanol
• EtOH ethanol
• EtOAc ethyl acetate
• Ac acetyl
• Hex hexane
• Me Me
• Et (ethyl); Ph phenyl
• DIEA diisopropylethylamine
• TFA trifluoroacetic acid
• DTT dithiothreitol
• THF tetrahydrofuran
• Solid-phase syntheses were performed by immobilizing reagents with Rink amide linkers (Rink, Tetrahedron Letters (1987) 28:3787), which are standard acid-cleavable linkers that upon cleavage generate a free carboxamide group.
• Rink amide linkers Rink, Tetrahedron Letters (1987) 28:3787
• Small-scale solid-phase syntheses e.g., about 2 - 5 ⁇ mole, were performed using Chiron SynPhase® polystyrene O-series crowns (pins) derivatized with Fmoc-protected Rink amide linkers.
• the Rink amide linkages were formed to Argonaut Technologies Argogel® resin, a grafted polystyrene-poly(ethylene glycol) copolymer.
• Any suitable resin may be used as the solid phase, selected from resins that are physically resilient and that, other than with regard to the linking and cleavage reactions, are inert to the synthetic reaction conditions.
• Example A(2) 6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4- dione.
• Example A(82) The title compound was prepared analogously to Example A(82), where 4-Bromo-1- ethoxy-2-methyl-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
• Example A(4) 6-Cyclopentyl-6-[2-(4-isopropoxy-3-methyl-phenyl)-ethyl]-dihydro-pyran-2,4- dione.
• Example A(6) 6-Cyclopentyl-6-(4-methoxy-phenylsulfanylmethyl)-dihydro-pyran-2,4-dione.
• Step 1 2-Chloro-1-cyclopentyl-et anone.
• Step 2 1-Cyclopentyl-2-(4-methoxy-phenylsulfanyl)-ethanone.
• Example A(7) N- ⁇ 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenyl ⁇ -acetamide.
• Example A(64) The title compound was prepared analogously to Example A(64), where ⁇ /-(4-Bromo-2- fluoro-phenyi)-acetamide was substituted in place of 4-bromo-2-fluoro-1-isopropylbenzene of that example.
• Step 1 2-(4-Bromo-2-fluoro-phenyl)-benzo[b]thiophene
• Methyl acetoacetate (0.66g, 5.7mmol) was added to a cooled 0 °C suspension of NaH (0.23 g, 5.7 mmol, 60% dispersion in mineral oil) in THF (10ml). After 30 min n-BuLi (2.3mL,
• Step 1 3-Cyclohex-1-enyl-propionic acid ethyl ester.
• Step 3 3-Cyclohex-1-enyl-thiopropionic acid S-pyridin-2-yl ester.
• Step 4 3-Cyclohex-1-enyl-1-cyclopentyl-propan-1-one. ⁇ TB-4059-095 ⁇
• Example A(14) 6-Cyclopentyl-6-[2-(2-oxo-pyrrolidin-1-yl)-ethyl]-dihydro-pyran-2,4-dione.
• Step 2 1-(3-Cyclopentyl-3-oxo-propyl)-pyrrolidin-2-one.
• the solid was suspended in pyridine (20mL) and treated with acetic anhydride (4.24mL, 45mmol). The mixture was refluxed for 2 h and then stirred at rt for 15h. The reaction mixture was partitioned between 2N HCl and EtOAc. The organic layer was washed with 1 N HCl, saturated NaHC0 3 , brine, dried over Na 2 S0 4 and concentrated. The residue was purifed by silica gel chromatography (5% hexanes in EtOAc), to give the title compound as a white solid, (1.1g, 29% yield).
• Example A(64) The title compound was prepared analogously to Example A(64), where 4-Bromo- ⁇ /- ethyl-2-fluoro-benzamide (described below), was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene of that example.
• Stepl 4-Bromo-W-ethyl-2-fluoro-benzamide.
• Example A(64) The title compound was prepared analogously to Example A(64), where 4-(4-Bromo- phenyl)-3,5-dimethyl-isoxazole (described below) was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene of that example.
• Step 1 4-(4-Bromo-phenyl)-3,5-dimethyl-isoxazole
• Step 1 [3(1 "R),4R]-3-[2'-(5"-Methoxy-1 "-indanyl)acetyl]-4-(phenylmethyl)-2-oxazolidinone (A) and [3(1 "S),4R]-3-[2'-(5"-Methoxy-1 "-indanyl)acetyl]-4-(phenylmethy l)-2-oxazolidinone (B):
• Step 3 (5-Methoxy-indan-1-yl)-thioacetic acid S-pyridin-2-yl ester.
• Methoxy-indan-1-yl)-acetic acid (from Step 2 below) was substituted in place of 3-Cyclohex-1- enyl-propionic acid.
• Step 4 1-Cyclopentyl-2-(5-methoxy-indan-1-yl)-ethanone.
• Example A(22) 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione.
• Step 3 Acetic acid 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-ethyl- phenyl ester.
• Step 1 N-Methoxy ⁇ 3-(4 ⁇ methoxy-phenyl)-N-methyl-propionamide.
• N.O-dimethylhydroxylamine hydrochloride (5.41g, 55.5mmol), EDC (12.77g, 66.6mmol), followed by triethylamine (17mL, 122mmol) were added to a cooled 0°C solution of 3-(4- methoxyphenyl)propionic acid (10g, 55.5mmol).
• the reaction mixture was stirred for 15h under N 2 and then concentrated.
• the residue was partitioned between 1 N HCl and EtOAc.
• the organic layers were washed with saturated NaHC0 3 , brine, dried over Na 2 S0 4 and concentrated to an oil.
• the oil was purified by silica gel chromatography (40% EtOAc in hexanes) to give a clear oil (10.6g, 85%).
• Step 2 1-(4-Methoxy-phenyl)-pentan-3-one.
• Step 1 3-(4-Methoxy-phenyl)-thiopropionic acid S-pyridin-2-yl ester.
• Step 2 1-(4-Methoxy-phenyl)-5-methyl-hexan-3-one.
• Example A(23) The title compound was prepared analogously to Example A(23), where allyl magnesium chloride was substituted in place of ethylmagnesium bromide in Step 2 of that Example.
• Step 1 4-Bromo-2-chloro-thiobenzoic acid S-pyridin-2-yl ester.
• Step 2 1-(4-Bromo-2-chloro-phenyl)-ethanone.
• Step 3 3-(4-Acetyl-3-chloro-phenyl)-1-cyclopentyl-propan-1-one.
• Example A(27) The title compound was prepared analogously to Example A(27), where 3-Bromo acetophenone was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example.
• Step 1 5-(3-Bromo-phenyl)-5-methyl-dihydro-furan-2-one
• Example A(27) The title compound was prepared analogously to Example A(27), where (4-Bromo- phenyl)-cyclopropyl-methanone was substituted in place of 1-(4-Bromo-2-chloro-phenyl)- ethanone in Step 3 of that example.
• Example A(27) The title compound was prepared analogously to Example A(27), where (4-Bromo- phenyl)-cyclopropyI-methanone was substituted in place of 1-(4-Bromo-2-chloro-phenyl)- ethanone in Step 3 of that example.
• the title compound was obtained side product previously described Example A(31).
• This compound was prepared as described in the following reference: Tetrahedron 2001 , 57, 5027-5038.
• This compound was prepared as described in the following reference: Tetrahedron 2001 , 57, 5027-5038.
• Step 1 (R) W-[1-(4-Bromo-phenyl)-ethyl]-malonamic acid ethyl ester.
• Step 1 (R) 1-[1-(4-Bromo-phenyl)-ethyl]-3-methyl-urea
• Step 1 (R) W-[1-(4-Bromo-phenyl)-ethyl]-methanesulfonamide.
• Step 1 (R)-5-Methyl-isoxazole-3-carboxylic acid [1-(4-bromo-phenyl)-ethyl]-amide.
• Step 1 4'-Bromo-biphenyl-3-carbonitrile.
• Step 1 2-(4-Bromo-phenyl)-W-methyl-isobutyramide.
• Step 1 2-(4-Bromo-phenyl)-W-ethyl-isobutyramide
• Step 1 2-(4-Bromo-2-fluoro-phenoxy)-2-rnethyl-propionic acid methyl ester.
• Step 1 2-[2-Chloro-4-(3-cyclopentyl-3-oxo-propyl)-phenoxy]-2-methyl-propionic acid methyl ester.
• Example A(53) The title compound was prepared analogously to Example A(53), where [2-Chloro-4-(3- cyclopentyl-3-oxo-propyl)-phenoxy]-acetic acid methyl ester (described in Step 1 below) was substituted in place of 2-[2-Chloro-4-(3-cyclopentyl-3-oxo-propyl)-phenoxy]-2-methyl-propionic acid methyl ester) of that example.
• Step 1 [2-Chloro-4-(3-cyclopentyl-3-oxo-propyl)-phenoxy]-acetic acid methyl ester.
• Example A(27) The title compound was prepared analogously to Example A(27), where 2-(4-Bromo-2- fluoro-phenoxy)-2-methyl-propionic acid methyl ester (described in Step 1 of Example A(52), was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example.
• Step 1 3-[1 -(4-Bromo-phenyl)-1 -methyl-ethyl]-5-methyl-[1 ,2,4]oxadiazole
• Example A(58) 6-Cyclopentyl-6-[2-(4-difluoromethoxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione.
• Step l 3-(4-Propoxy-phenyl)-propionic acid.
• Step 1 2-(4-bromo-2-fluorophenyl)propan-2-ol
• Step 2 4-bromo-2-fluoro-1 -isopropylbenzene
• Step 3 6-[2-cyclopentyl-4-(3-fluoro-4-isopropylphenyl)-2-hydroxybut-3-ynyl]-2,2-dimethyl- 4H-1 ,3 ⁇ dioxin-4-one.
• Step 1 4-bromo-2-ethyl-1 -f luorobenzene
• Example A(66) 6-Cyclopentyl-6-[2-(3-ethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione.
• Example A(86) The title compound was prepared analogously to Example A(86), where 3-Bromo- ethylbenzene was substituted in place of 1-(4-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
• Example A(86) The title compound was prepared analogously to Example A(86), where (3-Bromo- phenyl)-acetic acid methyl ester was substituted in place of 1-(4-Bromo-phenyl)- cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
• Step 1 1-(3-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester.
• HATU 169.6 mg, 0.4464 mmol
• 6- ⁇ 2-[3-(2-Amino-1,1- dimethyl-ethyl)-phenyl]-ethyl ⁇ -6-cyclopentyl-dihydro-pyran-2,4-dione trifluoroacetic acid salt (175 mg, 0.372 mmol), Et 3 N (207 ⁇ L, 1.488 mmol), 1H-Pyrazole-3-carboxylic acid (50.0 mg, 0.4464 mmol), dissolved in DMF (2 mL). The reaction was stirred overnight, then purified directly by
• Step 1 [2-(3-Bromo-phenyl)-2-methyl-propyl]-carbamic acid tert-butyl ester
• Step 2 (2- ⁇ 3-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl ⁇ -2-methyl- propyl)-carbamic acid tert-butyl ester
• Step 3 6- ⁇ 2-[3-(2-Amino-1,1-dimethyl-ethyl)-phenyl]-ethyl ⁇ -6-cyclopentyl-dihydro-pyran- 2,4-dione trifluoroacetic acid salt
• the desired product was prepared analogously to Step 5 of Example A(86), substituting 2- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-t1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl ⁇ -2- methyl-propionitrile (1.23 g, 2.9 mmol) from Step 3 below in place of 1- ⁇ 4-[3-Cyclopentyl-4-(2,2- dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl ⁇ -cyclopropanecarbonitrile. Yield: 0.614 g, 56 %.
• Step 2 2- ⁇ 4-[3-Cyclopenty!-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2-fluoro-phenyl ⁇ -2-methyl-propionitrile
• Step 3 2- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-butyl]-2- fluoro-phenyl ⁇ -2-methyl-propionitrile
• the desired product was prepared analogously to example A(86), Step 6, substituting 2- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyi-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl ⁇ -2-methyl-propionitrile (1.25 g, 2.9 mmol) from Step 2 above in place of 1- ⁇ 4-[3- Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl ⁇ - cyclopropanecarbonitrile. Yield: 1.23 g, 99%.
• the aqueous layer was extracted with 2 x 100 mL CH 2 CI 2 and the organic layers were combined. After drying the organic with MgS0 4l and filtering to remove the solids, the solvent was removed by rotary evaporation. The remaining oil was purified by flash chromatography to yield the desired product (0.367 g, 47%).
• Step 4 6-(2-Cyclopentyl-2-hydroxy-4-trimethylsilanyl-but-3-ynyl)-2,2-dimethyl-[1,3]dioxin- 4-one
• Step 5 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-e-oxo-6H-[1,3]dioxin-4-yl)-3 hydroxy-but-1- ynyl]-2-fluoro-phenyl ⁇ -cyclopropanecarbonitrile
• the desired product was prepared analogously to example F(7), Step 5, substituting 1-(4- bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile (0.96 g, 4.0 mmol), from Step 2 above in place of 3-iodophenol, and 6-(2-cyclopentyl-2-hydroxy-but-3-ynyl)-2,2-dimethyl-[1,3]dioxin-4-one (1.06 g, 4.0 mmol; from Step 4 above) in place of 6-but-3-ynyl-3-chloro-6-cyclopentyl-dihydro-pyran-
• Step 6 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2- fluoro-phenyl ⁇ -cyclopropanecarbonitrile
• Methane sulfonyl chloride (1.93ml, 0.025M) was added to a solution of 4-bromo-2-ethylaniline (5.0g, 0.025M) and pyridine (2.02ml, 0.025M) ⁇ dichloromethane (100ml) at 0°C.
• the reaction mixture was stirred for lhr, after which time it was partitioned between dichloromethane (100ml) and IN hydrochloric acid (100ml). The organics were separated and dried over magnesium sulfate, filtered and concentrated in vacuuo to afford the title compound as a clear oil (4.77g).
• Step 2 ⁇ /-(4-bromo-2-ethylphenyl)- ⁇ /-methylmethanesulfonamide
• Methyl iodide (1.6g, 0.0256M) was added to a mixture ofN-(4-bromo-2- ethylphenyl)methanesulfonamide (4.77g, 0.0171M) and potassium carbonate (3.5g, 0.0256M) in dimethylformamide (50ml) at room temperature under an atmosphere of nitrogen.
• the reaction mixture was stirred for a further 24hrs after which time it was partitioned between diethylether (100ml) and water (100ml). The aqueous was extracted further with diethyl ether (2x100ml). The combined organics were dried over magnesium sulfate, filtered and the solvent concentrated in vacuuo to afford the title compound as a brown oil (3.6g).
• Step 2 /-(4-bromophenyl)-N-methylmethanesulfonamide
• Methyl iodide (2.38g, 0.0382yi) was added to a mixture of ⁇ /-(4- bromophenyl)methanesulfonamide 6.37g, 0.0255M) and potassium carbonate (5.21 g, 0.0382M in dimethylformamide (50ml) at room temperature under an atmosphere of nitrogen.
• the reaction mixture was stirred for a further 24(jrs after which time it was partitioned between diethylether (100ml) and water (100ml). The aqueous was extracted further with diethyl e her (2x100ml). The combined organics were dried over magnesium sulfate, filtered and the solvent" concentrated in vacuuo to afford the title compound as a white solid (5.6g).
• Example A(22) The title compound was prepared analogously to Example A(22): where 4-bromo-2- cyclopentylphenol, from step 1 , was used in place of 4-Bromo-2-ethyl-phenol in step 2 of that example.
• Step 2 2- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2-fluoro-phenyl ⁇ -2-ethyl-butyronitrile
• the desired product was prepared analogously to Example A(86) step 5, substituting 2- (4-Bromo-2-fluoro-phenyl)-2-ethyl-butyronitrile (1.01 g, 4.0 mmol) from step 1 above in place of 1- (4-bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 0.953 g, 53 %.
• the desired product was prepared analogously to example A(86) step 6, substituting 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl ⁇ -2-ethyl-butyronitrile (0.900 g, 2.0 mmol) from step 2 above in place of 1- ⁇ 4-[3- Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl ⁇ - cyclopropanecarbonitrile. Yield: 0.841 g, 92%.
• the desired product was prepared analogously to Example A(86) step 5 substituting 1- ⁇ 4- [3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl ⁇ - cyclobutanecarbonitrile (1.00 g, 2.2 mmol) from step 3 below in place of 1- ⁇ 4-[3-Cyclopentyl-4- (2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl ⁇ - cyclopropanecarbonitrile. Yield: 0.477 g, 57 %.
• the desired product was prepared analogously to Example A(86) step 5, substituting 1- (4-Bromo-2-fluoro-phenyl)-cyclobutanecarbonitriie (1.06 g, 4.0 mmol) from step 1 above in place of 1-(4-bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 1.226 g, 70 %.
• Step 3 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-butyl]-2- fluoro-phenylj-cyclobutanecarbonitrile
• the desired product was prepared analogously to Example A(86) step 6, substituting 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-di ⁇ f ⁇ ethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl ⁇ -cyclobutanecarborjjtrile (1.200 g, 2.7 mmol) from' step 2 above in place of 1- ⁇ 4-[3- Cyclopentyl-4-(2,2-dimethyJ-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl ⁇ - cyclopropanecarbonitrile. Yield: 1.00 g, 84%.
• Example A(94) The title compotl ⁇ d was prepared analogously to Example A(22)where Acetic acid 4-[2- (2-cyclopentyl-4,6-diox ⁇ tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-phenyl ester (Example A(94) ) was substituted in place Jj ⁇ f acetic acid 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]- 2-ethyl-phenyl ester.
• Step 4 Preparation of compound 2- ⁇ 4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2W-pyran-2- yl)ethyl]-2-fluorophenyl ⁇ -2-methylpropanenitrile.
• the crude mixture was dissolved in anhydrous MeOH (100 mL) and treated with K 2 C0 3 (2.8 g, 10 mmol). The reaction was heated at 45 °C for 40 min before it was cooled down to room temperature. The crude mixture was diluted with aqueous NH CI and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine, dried over Na 2 S0 4 . The solvent was removed and the mixture was purified by flash column chromatography (EtOAc in hexanes, 10-40 % gradient) to give the desired product (1.4 g, 35% for two steps).
• Step 3 Preparation of compound 2- ⁇ 4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6- yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl ⁇ -2-methylpropanenitrile
• Step 1 4-chloro-/V 1 -methylbenzene-1,2-diamine

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Virology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Gastroenterology & Hepatology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Molecular Biology (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pyrane Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (7)

Applications Claiming Priority (4)

Publications (3)

Family

ID=32912318

Family Applications (1)

Country Status (15)

Cited By (40)

Families Citing this family (13)

Family Cites Families (19)

• 2003
  • 2003-11-19 US US10/718,337 patent/US7148226B2/en not_active Expired - Fee Related
• 2004
  • 2004-02-09 WO PCT/IB2004/000493 patent/WO2004074270A2/en not_active Ceased
  • 2004-02-09 EP EP04709301A patent/EP1597246A2/en not_active Withdrawn
  • 2004-02-09 MX MXPA05007133A patent/MXPA05007133A/es not_active Application Discontinuation
  • 2004-02-09 BR BR0407699-0A patent/BRPI0407699A/pt not_active IP Right Cessation
  • 2004-02-09 JP JP2006502472A patent/JP3940430B2/ja not_active Expired - Fee Related
  • 2004-02-09 AU AU2004213247A patent/AU2004213247A1/en not_active Withdrawn
  • 2004-02-09 CA CA002516235A patent/CA2516235A1/en not_active Abandoned
  • 2004-02-17 PA PA20048596001A patent/PA8596001A1/es unknown
  • 2004-02-17 US US10/783,117 patent/US20040224960A1/en not_active Abandoned
  • 2004-02-18 UY UY28192A patent/UY28192A1/es not_active Application Discontinuation
  • 2004-02-20 NL NL1025544A patent/NL1025544C2/nl not_active IP Right Cessation
  • 2004-02-20 PE PE2004000179A patent/PE20050289A1/es not_active Application Discontinuation
  • 2004-02-20 TW TW093104282A patent/TW200426143A/zh unknown
  • 2004-02-20 AR ARP040100543A patent/AR044749A1/es unknown
• 2005
  • 2005-06-16 IS IS7896A patent/IS7896A/is unknown
• 2006
  • 2006-05-08 US US11/382,154 patent/US7473790B2/en not_active Expired - Fee Related

Also Published As

Similar Documents

Legal Events